Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody.
Identifieur interne : 001707 ( PubMed/Corpus ); précédent : 001706; suivant : 001708Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody.
Auteurs : C R Honey ; H. ShenSource :
- Journal of neurosurgery [ 0022-3085 ] ; 1999.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (therapeutic use), Cyclosporine (therapeutic use), Disease Models, Animal, Fetal Tissue Transplantation, Immunosuppression (methods), Immunosuppressive Agents (therapeutic use), Male, Mesencephalon (transplantation), Mice, Parkinson Disease, Secondary (surgery), Rats, Rats, Wistar, Receptors, Interleukin-2 (immunology), Transplantation, Heterologous, Treatment Outcome.
- MESH :
- chemical , immunology : Receptors, Interleukin-2.
- chemical , therapeutic use : Antibodies, Monoclonal, Cyclosporine, Immunosuppressive Agents.
- methods : Immunosuppression.
- surgery : Parkinson Disease, Secondary.
- transplantation : Mesencephalon.
- Animals, Disease Models, Animal, Fetal Tissue Transplantation, Male, Mice, Rats, Rats, Wistar, Transplantation, Heterologous, Treatment Outcome.
Abstract
The goal of this study was to compare the effects of short- and long-term immunosuppression induced by cyclosporin with those of immunosuppression induced by a monoclonal antibody against the rat interleukin-2 receptor (anti-CD25 mAb) in rats with xenografts.
DOI: 10.3171/jns.1999.91.1.0109
PubMed: 10389888
Links to Exploration step
pubmed:10389888Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody.</title>
<author><name sortKey="Honey, C R" sort="Honey, C R" uniqKey="Honey C" first="C R" last="Honey">C R Honey</name>
<affiliation><nlm:affiliation>Division of Neurosurgery, University of British Columbia, Vancouver, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shen, H" sort="Shen, H" uniqKey="Shen H" first="H" last="Shen">H. Shen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10389888</idno>
<idno type="pmid">10389888</idno>
<idno type="doi">10.3171/jns.1999.91.1.0109</idno>
<idno type="wicri:Area/PubMed/Corpus">001707</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001707</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody.</title>
<author><name sortKey="Honey, C R" sort="Honey, C R" uniqKey="Honey C" first="C R" last="Honey">C R Honey</name>
<affiliation><nlm:affiliation>Division of Neurosurgery, University of British Columbia, Vancouver, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Shen, H" sort="Shen, H" uniqKey="Shen H" first="H" last="Shen">H. Shen</name>
</author>
</analytic>
<series><title level="j">Journal of neurosurgery</title>
<idno type="ISSN">0022-3085</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (therapeutic use)</term>
<term>Cyclosporine (therapeutic use)</term>
<term>Disease Models, Animal</term>
<term>Fetal Tissue Transplantation</term>
<term>Immunosuppression (methods)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Male</term>
<term>Mesencephalon (transplantation)</term>
<term>Mice</term>
<term>Parkinson Disease, Secondary (surgery)</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Receptors, Interleukin-2 (immunology)</term>
<term>Transplantation, Heterologous</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Receptors, Interleukin-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Cyclosporine</term>
<term>Immunosuppressive Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunosuppression</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Mesencephalon</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Fetal Tissue Transplantation</term>
<term>Male</term>
<term>Mice</term>
<term>Rats</term>
<term>Rats, Wistar</term>
<term>Transplantation, Heterologous</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The goal of this study was to compare the effects of short- and long-term immunosuppression induced by cyclosporin with those of immunosuppression induced by a monoclonal antibody against the rat interleukin-2 receptor (anti-CD25 mAb) in rats with xenografts.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10389888</PMID>
<DateCreated><Year>1999</Year>
<Month>07</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>07</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3085</ISSN>
<JournalIssue CitedMedium="Print"><Volume>91</Volume>
<Issue>1</Issue>
<PubDate><Year>1999</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Journal of neurosurgery</Title>
<ISOAbbreviation>J. Neurosurg.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody.</ArticleTitle>
<Pagination><MedlinePgn>109-13</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="OBJECT" NlmCategory="OBJECTIVE">The goal of this study was to compare the effects of short- and long-term immunosuppression induced by cyclosporin with those of immunosuppression induced by a monoclonal antibody against the rat interleukin-2 receptor (anti-CD25 mAb) in rats with xenografts.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The authors compared the in vivo function and final histological characteristics of fetal mouse mesencephalon xenografts in hemiparkinsonian rats in which immunosuppression was induced by: 1) a short course (2 weeks) of cyclosporin; 2) a long course (8 weeks) of cyclosporin; or 3) a short course of treatment with anti-CD25 mAb. Adult Wistar rats were unilaterally lesioned with 6-hydroxydopamine in their medial forebrain bundle, after which their rotational behavior in response to methamphetamine was quantified. Four groups of 20 rats with rotations numbering greater than six turns per minute received fetal mouse mesencephalon transplants to their dopamine-denervated striatum. Group 1 received no immunosuppression therapy; Group 2 received daily intraperitoneal injections of 10 mg/kg cyclosporin for 2 weeks; Group 3 received daily intraperitoneal injections of 10 mg/kg cyclosporin for 8 weeks; and Group 4 received daily intraperitoneal injections of 1 mg/kg anti-CD25 mAb for 2 weeks. The rats were tested for rotational behavior every 4 weeks and killed after 16 weeks. Surviving xenografts were assessed using immunohistochemical staining for a mouse neuronal marker (Thy-1.2). Sixteen weeks after transplant, there were significantly more surviving xenografts in Groups 3 (p < 0.001) and 4 (p < 0.001) compared with control Group 1 (Fisher's exact test) and significantly better functioning xenografts in Groups 3 (p < 0.01) and 4 (p < 0.05) compared with control Group 1 (contrasts of groups following analysis of variance with Bonferroni correction).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A short course of anti-CD25 mAb-induced immunosuppression was as effective as a long course of cyclosporin-induced immunosuppression in this model.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honey</LastName>
<ForeName>C R</ForeName>
<Initials>CR</Initials>
<AffiliationInfo><Affiliation>Division of Neurosurgery, University of British Columbia, Vancouver, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Neurosurg</MedlineTA>
<NlmUniqueID>0253357</NlmUniqueID>
<ISSNLinking>0022-3085</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber>
<NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016332" MajorTopicYN="N">Fetal Tissue Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName>
<QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015375" MajorTopicYN="N">Receptors, Interleukin-2</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year>
<Month>7</Month>
<Day>2</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1999</Year>
<Month>7</Month>
<Day>2</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1999</Year>
<Month>7</Month>
<Day>2</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10389888</ArticleId>
<ArticleId IdType="doi">10.3171/jns.1999.91.1.0109</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001707 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001707 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:10389888 |texte= Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10389888" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |